Carolyn Pace, MD
Rheumatology · Tempe, AZNPI 1578594974
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $19,108 of the $25,486 with a category attached, or 75.0%. It is spread thinly across 34 manufacturers, the largest accounting for just 21.6%.
Across 1,190 payments — averaging $21.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$5K
- AbbVie$4K
- UCB, Inc.$4K
- Bristol Myers Squibb$2K
- AstraZeneca$2K
- GSK$1K
- plus $7K from 28 others
What the payments were for
- Consulting fees$5,40521%
- Travel & lodging$9264%
- Food & beverage$19,10875%
- Education$470%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 235 | $5,498 |
| AbbVie | 227 | $3,876 |
| UCB, Inc. | 93 | $3,538 |
| Bristol Myers Squibb | 18 | $2,391 |
| AstraZeneca | 78 | $1,568 |
| GSK | 106 | $1,433 |
| Pfizer | 109 | $1,422 |
| Johnson & Johnson(2 entities) | 103 | $1,251 |
| Lilly USA, LLC | 45 | $1,171 |
| Novartis | 49 | $778 |
| Sanofi | 29 | $565 |
| E.r. Squibb & Sons, L.L.C. | 25 | $385 |
| Mallinckrodt Hospital Products Inc. | 18 | $378 |
| Sobi, Inc | 13 | $295 |
| Boehringer Ingelheim | 12 | $215 |
| Janssen Scientific Affairs, LLC | 1 | $125 |
| Fresenius Kabi USA, LLC | 3 | $83 |
| Sandoz | 4 | $74 |
| Vertex | 2 | $52 |
| Almatica Pharma LLC | 2 | $45 |
| Genentech USA, Inc. | 2 | $43 |
| Actelion Pharmaceuticals US, Inc. | 2 | $43 |
| Organon | 2 | $36 |
| Mylan Institutional Inc. | 2 | $36 |
| Invivyd Inc | 1 | $30 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $22 |
| Ultragenyx Pharmaceutical Inc. | 1 | $19 |
| Radius Health, Inc. | 1 | $18 |
| Emergent Biosolutions Inc. | 1 | $17 |
| Medexus Pharma, Inc. | 1 | $16 |
| Sanofi-aventis U.S. LLC | 1 | $16 |
| Mallinckrodt Enterprises LLC | 1 | $15 |
| Optos, Inc. | 1 | $15 |
| Qiagen, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$25,486 in reported general payments places this provider in the 80th percentile of 102 rheumatology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf)Adalimumab | 22 | $390,685 |
| Enbrel SureclickEtanercept | 39 | $326,707 |
| RinvoqUpadacitinib | 32 | $240,643 |
| Orencia ClickjectAbatacept | 35 | $223,999 |
| BenlystaBelimumab | 38 | $220,635 |
| Humira(Cf) PenAdalimumab | 20 | $136,603 |
| OrenciaAbatacept/Maltose | 20 | $119,824 |
| CosentyxSecukinumab | 28 | $110,442 |
| Cimzia (2 Pack)Certolizumab Pegol | 15 | $85,450 |
| Xeljanz XrTofacitinib Citrate | 13 | $73,630 |
| SaphneloAnifrolumab-Fnia | 13 | $68,189 |
| RemicadeInfliximab | 11 | $51,394 |
| RasuvoMethotrexate/Pf | 20 | $18,056 |
| Hydroxychloroquine Sulfate | 315 | $12,815 |
| MethotrexateMethotrexate Sodium | 267 | $6,356 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieHumira(Cf), Rinvoq | $3,876 | $631,32854 claims |
| GSKBenlysta | $1,433 | $220,63538 claims |
| E.r. Squibb & Sons, L.L.C.Orencia | $385 | $119,82420 claims |
| NovartisCosentyx | $778 | $110,44228 claims |
| UCB, Inc.Cimzia (2 Pack) | $3,538 | $85,45015 claims |
| AstraZenecaSaphnelo | $1,568 | $68,18913 claims |
| Johnson & JohnsonRemicade | $1,251 | $51,39411 claims |
| Medexus Pharma, Inc.Rasuvo | $16 | $18,05620 claims |
| Fresenius Kabi USA, LLCSodium Chloride | $83 | $338126 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 102 rheumatology providers in Arizona.
Other rheumatology in Tempe
- Nehad SolomanPhoenix$1.3M
- John TesserPhoenix$999K
- Joy SchechtmanPeoria$860K
- Mona AminGlendale$446K
- Brittany PanicoGilbert$374K
- Amer Al-KhoudariChandler$369K
- Andrew SharobeemGlendale$231K
- Paul HowardScottsdale$124K
- Sherif NasefYuma$111K
- Michael MaricicTucson$110K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.